DAXOR CORP 10-Q Summary: Period Ended June 30, 2000
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 2000, for DAXOR Corporation. The company operates in two primary segments: the sale of medical equipment (specifically the BVA-100 Blood Volume Analyzer) and the provision of localized semen and blood banking services. The company is actively transitioning its business model to prioritize equipment sales through distribution networks and leasing arrangements.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2000 | Six Months Ended June 30, 1999 |
|---|---|---|
| Total Revenues | $1,357,779 | $1,544,316 |
| Operating Revenues | $361,997 | $224,127 |
| Dividend Income | $939,545 | $922,995 |
| Net Income | $32,232 | $104,887 |
| Net Income Per Share | $0.01 | $0.02 |
| Cash Flow from Operations | $122,556 | ($267,458) |
| Total Assets | $37,989,145 | $35,846,065 |
| Marketable Securities (Fair Value) | $37,209,011 | $34,867,286 |
| Total Liabilities | $7,451,300 | $6,566,496 |
| Loans Payable | $2,636,983 | $2,443,794 |
Material Changes vs. Prior Period
- Revenue Composition: While total revenues decreased by approximately 12% year-over-year, operating revenues increased by 61% ($361,997 vs. $224,127), driven by sales of the BVA-100 Blood Volume Analyzer. This growth was offset by a significant decline in capital gains from the sale of securities ($6,005 in 2000 vs. $397,194 in 1999).
- Profitability: Net income decreased to $32,232 from $104,887 in the prior year, primarily due to the lack of significant capital gains in the current period. However, the company successfully reduced operating costs despite higher operating revenues.
- Liquidity and Debt: Cash and cash equivalents decreased from $67,783 to $36,625. Loans payable increased to $2.64 million, consisting of a $1 million bank loan and $969,474 in margin debt secured by marketable securities.
- Investment Portfolio: The company holds a substantial portfolio of "Available-For-Sale" securities with a fair value of $37.2 million, representing a net unrealized gain of $13.9 million (59.33% over cost).
Outlook, Risks, and Management Commentary
Management anticipates that equipment and kit sales will become the major source of income. The company is currently initiating distribution networks but has not yet received income from sales by non-company personnel. Strategic options under review include establishing a nationwide sales force versus utilizing independent dealer networks, and potentially acquiring additional capital to accelerate national and international marketing.
Risks and Contingencies:
- Capital Intensity: The company utilizes an "instrument loaner reagent plan" which requires the use of reserves and results in a slower return on capital expenditure compared to immediate sales or leases.
- Market Dependence: Future growth is heavily dependent on the successful marketing and adoption of the BVA-100 Blood Volume Analyzer.
- Debt Security: Significant short-term loans are secured by the company's marketable securities, creating potential liquidity risks if the portfolio value declines.
Investor Verification Checklist
- Verify the progress of distribution network agreements and the timeline for revenue recognition from third-party sales.
- Confirm the stability of the marketable securities portfolio, as it represents the majority of assets and secures the company's debt.
- Assess the impact of the "instrument loaner reagent plan" on cash flow and the timeline for transitioning to lease or sale models.
- Monitor the company's ability to fund national marketing efforts without diluting shareholders or increasing leverage significantly.